Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | TTK | P33981 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12490426 | 0.82 | NLRP3 (0.49) | NLRP3CYP1A2TTKALDH1A1CYP2C19 | |
| SCHEMBL3369232 | 0.81 | NLRP3 (0.56) | NLRP3CYP1A2TTKALDH1A1CYP2C19 | |
| SCHEMBL3349539 | 0.79 | NLRP3 (0.52) | NLRP3CYP1A2TTKALDH1A1HPGD | |
| SCHEMBL553902 | 0.77 | NLRP3 (0.56) | NLRP3CYP1A2TTKALDH1A1HPGD | |
| SCHEMBL12999920 | 0.77 | NLRP3 (0.50) | NLRP3CYP1A2TTKALDH1A1HPGD | |
| SCHEMBL2070169 | 0.77 | CYP1A2 (0.55) | NLRP3CYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL15053076 | 0.77 | KDM4E (0.46) | CYP1A2ALDH1A1HPGDHDAC1TSHR | |
| SCHEMBL856245 | 0.76 | CYP1A2 (0.50) | NLRP3CYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL31412793 | 0.76 | CYP1A2 (0.53) | NLRP3CYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL160214 | 0.76 | CYP1A2 (0.53) | NLRP3CYP1A2ALDH1A1HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2986604-B1 | PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2017-12-20 | — | — | EP | disclosed |
| EP-2797885-B1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2797884-B1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-04-13 | — | — | EP | disclosed |
| EP-2797884-B1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-04-13 | — | — | EP | disclosed |
| EP-2986604-A1 | PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2016-02-24 | — | — | EP | disclosed |
| US-8962641-B2 | Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-24 | — | — | US | disclosed |
| US-8962641-B2 | Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-24 | — | — | US | disclosed |
| US-8962641-B2 | Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-24 | — | — | US | disclosed |
| EP-2797884-A1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2014-11-05 | — | — | EP | disclosed |
| EP-2797885-A1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8623860-B2 | Azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623860-B2 | Azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8530461-B2 | Azetidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| US-20130172316-A1 | New azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172316-A1 | New azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172316-A1 | New azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| WO-2013098375-A1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | WO | disclosed |
| US-20130172312-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| WO-2013098373-A1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013098375-A1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172312-A1 | Azetidine Derivatives | GPR119, LIPE, LPL | NLRP3 1277/4885CYP1A2 181/4885TTK 4113/4885 |
| US-20130172316-A1 | New azetidine derivatives, pharmaceutical compositions and uses thereof | QDPR, AZI2, CYP2C19 | NLRP3 2244/4885CYP1A2 35/4885TTK 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.